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Background: Diminished bone mineral density (BMD) is of significant concern in pediatric inflammatory bowel disease
(IBD). Exact etiology is debatable. The recognition of fibroblast growth factor 23 (FGF23), a phosphaturic hormone related
to tumor necrosis factor alpha (TNF-α) makes it plausible to hypothesize its possible relation to this pathology.
Methods: In this follow up case control study, BMD as well as serum levels of FGF23, calcium, phosphorus, alkaline
phosphatase, creatinine, parathyroid hormone, 25 hydroxy vitamin D3 and 1, 25 dihydroxy vitamin D3 were measured in
47 children with IBD during flare and reassessed in the next remission.
Results: Low BMD was frequent during IBD flare (87.2%) with significant improvement after remission (44.7%). During
disease flare, only 21.3% of patients had vitamin D deficiency, which was severe in 12.8%. During remission, all patients
had normal vitamin D except for two patients with Crohn’s disease (CD) who remained vitamin D deficient. Mean value
of serum FGF23 was significantly higher among patients with IBD during flare compared to controls. It showed
significant improvement during remission but not to the control values. 1, 25 dihydroxy vitamin D3, FGF23, serum
calcium and urinary phosphorus were significant determinants of BMD in IBD patients.
Conclusions: We can conclude that diminished BMD in childhood IBD is a common multifactorial problem. Elevated
FGF23 would be a novel addition to the list of factors affecting bone mineral density in this context. Further molecular
studies are warranted to display the exact interplay of these factors.
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Children with inflammatory bowel disease demonstrate
decreased bone mineral density [1]. Risk factors include the
use of steroids [2], defective nutritional status [3] and the
inflammatory process itself [4]. While some studies recom-
mend the use of oral vitamin D and calcium for prevention
of bone loss in patients with IBD [5], no sufficient evidence
exists of vitamin D deficiency in these patients [6-8] or of
their benefit from vitamin D supplementation [9].
Fibroblast growth factor 23 (FGF23) belongs to the
group of phosphatonins, which enhance renal phosphate
excretion and inhibit renal 25-hydroxy-vitamin D3 1α
hydroxylase [10]. Increased FGF 23 secretion was proved* Correspondence: moshodhod@yahoo.com
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distribution, and reproduction in any mediumto be the mechanism of bone disease in many diseases
including tumor induced osteomalacia [11] and X-linked
hypophopshatemic rickets [12]. Decreased degradation
of FGF23 was found to be the mechanism of bone
disease in autosomal dominant hypophosphatemic
rickets [13]. Impaired renal excretion of FGF23 was
proved to be the mechanism of renal osteodystrophy and
post-transplant hypophosphatemia [14].
The PHEX (phosphate-regulating with homologies to
endopeptidases on the X chromosome) gene encodes a
Zinc-metalloendopeptidase expressed primarily in
osteoblasts and odontoblasts. Studies seemed to confirm
the hypothesis of proteolytic degradation of FGF-23 by
PHEX [15]. The down-regulation of the PHEX gene
results in decreased degradation of FGF-23 and a
subsequent increase in its circulating levels [16].tral Ltd. This is an Open Access article distributed under the terms of the
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genesis of IBD [17]. Uno et al. demonstrated that in ex-
perimental animals, TNF-alpha decreases Phex mRNA
and protein expression via a transcriptional mechanism
and this is at least in part responsible for inhibition of
osteoblast mineralization [18].
Hypothesis
We hypothesize that FGF23 is increased in patients with
IBD and, being a phosphaturic hormone, may contribute
to the diminished BMD noticed in this patient popula-
tion. So the aim was to assess relation of serum FGF-23
to BMD among children with IBD.
Subjects and methods
This follow up case control clinical study included 47
children with IBD (27 with ulcerative colitis "UC" and 20
with Crohn’s disease "CD") recruited from amongst IBD
patients followed up at the Pediatric Gastroenterology
Unit, Ain Shams University Faculty of Medicine over the
period from December 2008 to December 2010. They
were 32 males (14 UC and 18 CD) and 15 females (13
UC and 2 CD), with a mean age of 11.6 ± 3.5 years.
Patients were studied during disease activity, either at initial
diagnosis (6 UC and 5 CD) or in a disease relapse (21 UC
and 15 CD). Patients underwent clinical and laboratory re-
assessment 3 months after achieving remission depending
on feasibility of follow up visits and availability of required
tests as DXA scan. The duration between the initial evalu-
ation "flare" and reassessment "remission" ranged between
4 and 9 months (mean of 7.12 +/− 2.8 months). Fifty
healthy, age and sex matched children (12 males and 9
females with an age range of 4–16 years and a mean age of
12.8 ± 3.77 years) were included as a control group.
Inclusion criteria
1- Diagnosis of IBD based on the Porto criteria [19].
2- Disease flare that was assessed using Pediatric
Ulcerative Colitis Activity Index (PUCAI) for UC
[20] and modified Pediatric Crohn’s disease Activity
Index (PCDAI) for CD [21].
3- No steroid therapy for at least three months prior to
enrollment in this study.
Exclusion criteria
1- Critically ill patients who cannot be transferred for
DXA procedure.
2- Concomitant endocrinal, renal or genetic bone diseases.
Plan of work
After approval of the study by the local ethics commit-
tee, informed consents were taken from the guardians of
all patients, as well as assents from older children.A full medical history and general examination, including
anthropometric assessment of height for age with its Z
score as well as body mass index (BMI), were done [22].
Laboratory assessment included complete blood count
[Coulter 1660], C-reactive protein [AVITEX- CRP latex
test [23]], ESR [Westergren method [24]], serum calcium
[colorimetric method [25]], serum alkaline phosphatase
[autoanalyzer], serum phosphorus [direct UV method
without reduction [26]] and urinary phosphorus [colori-
metric methods using an autoanalyzer (Multistat III Plus,
Instrumentation Laboratory, Inc, Lexington, MA)].
Colonoscopy and esophago-gastrodudenoscopy [Pentax
videosopes, PENYAX GmbH CO. Juulius Vosseler
Strasse 104, 22527 Hamburg, Germany] with histopatho-
logic assessment of multiple biopsies were done for all
patients. Serum creatinine was measured using Synchron
cx7 (Beckman Inc.).
Measurement of 25 (OH) D3 was done using radioio-
dine (125I)-based RIA kits (DiaSorin, Stillwater, MN) [27]
with unit of measurement being ng/ml. Values below
15 ng/ml were considered indicative of vitamin D
deficiency [28] and values below 8 ng/ml were
considered indicative of severe vitamin D deficiency
[29]. Measurement of 1, 25 (OH)2 D3 was done using
Human 1, 25-Dihydroxy-Vitamin D RIA Kit (IBL
International GmbH) with unit of measurement being
pg/ml [30]. PTH level was measured by the Immulite
2000 Intact PTH assay.
Serum FGF23 was measured using a C-terminal
human FGF23 ELISA (Immunotopics, San Clemente,
CA) [31]. The plasma was stored at –20 C till assessment
at end of study. It was expressed as a concentration of
pg/ml with a sensitivity of 4 pg/ml.
Bone densitometry
BMD was determined by DXA Lunar scan [DPX-MD
2001, GE medical systems, USA]. Device was calibrated
daily, and the technical error calculated to be less than
1%. Z-scores were calculated from BMD values using the
reference data for bone density for age and sex [32] and
corrected to bone age which was assessed from X Rays
of the left hand [33]. The values of total body BMD were
used for analysis.Values between −1.0 and −2.5 denoted
a mild decrease in BMD and < −2.5 were diagnostic of
severe decrease [34].
Treatment
For induction of remission, all patients received oral
prednisone (1–2 mg/kg/day) for 3–4 weeks. Parenteral
antibiotics and other supportive measures were individu-
ally adjusted. After induction of remission, patients were
then maintained on 5 amino salicylic acid [35]. Six CD
patients subsequently received infliximab as add-on
therapy [36]. One patient with UC underwent total
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sion was defined as PUCAI < 10 points for UC [20] and
PCDAI < 15 points for CD [21].
Nutritional support after enrollment in the flare state
included calcium (500 – 1000 mg daily) and oral vitamin
D3 supplementation as 1000 IU daily for non-deficient
and 10000 IU daily for deficient children.
Regarding the physical activity, patients, prior to flare,
were not bed ridden but were ambulant and most of
them were attending their full-day school activities. The
hospital admission ranged between 3–4 weeks. The
remaining time till reassessment was spent with their
normal range of activity with the exception of strenuous
exercises. An exception was one patient with CD who
had multiple vertebral fractures with marked decrease of
BMD. However we did not quantify physical activities to
consider them in analysis.Statistical methods
The computer program SPSS for Windows, release 10.0
(SPSS, inc, Chicago, IL, USA) was used for data entry and
analysis. All quantitative data were analyzed as mean and
standard deviation (SD). Student’s t test was used to com-
pare quantitative data between different groups. Chi square
test was used to compare qualitative variables between dif-
ferent groups. Multiple regression analysis was performed.Results
The duration of illness from definitive diagnosis of IBD
ranged from 0 to 48 months, while the duration from
the first complaint till inclusion in the study ranged from
6 to 60 months.
Patients of the UC group were significantly older than
the CD group (12.77 +/−1.71 and 10.49 +/− 3.34 years
respectively). Both were comparable to the control group
(11.86 +/−3.39 years; p value 0.228 and 0.202 respect-
ively). The male to female ratio was 18:2 in the CD
group, and 14:13 in the UC group (p = 0.006).
Bleeding per rectum and joint involvement (arthralgia
or arthritis) were more frequently encountered among
patients with UC (100%, 48.15% and 48.15% respectively)
than CD (35%, 10% and 15% respectively). One of the
included patients had pathological fractures of the last 3
lumbar spines.
The mean values of Z score of height-for-age was
significantly lower in children with disease activity
compared to controls (p < 0.001). Both groups showed a
non-significant improvement after remission which remain
significantly lower than controls (p < 0.001).
BMI was significantly lower in UC and CD patients
during flare (17.26 +/− 2.34 and 17.13 +/− 2.46 respect-
ively) and remission (19.27 +/− 2.07 and 20.27 +/− 3.18
respectively) than in the control group (25.43 +/−2.65)(p < 0.001). The difference between flare and remission
was significant for both UC (p = 0.002) and CD (p = 0.001).
Bone mineral density and Z score of corrected BMD to
bone age and sex were both significantly lower during
disease activity compared to values at remission (Table 1).
Severe affection (Z score < −2.5) was present in 88.9% and
75% of patients with active UC and CD respectively. After
remission, this decreased to 37% and 10% of patients with
UC and CD, respectively (Table 2). The rate of change
of Z score of corrected BMD to bone age showed no
significant difference between the UC and CD groups
(Table 3).
Serum calcium was significantly lower in UC and CD
patients during both disease activity (9.45 +/− 0.45 and
9.26 +/− 0.34 mg/dl respectively) and after disease
remission (9.55 +/− 0.43 and 9.500 +/− 0.67 mg/dl respect-
ively) compared to the control group (9.78 +/− 0.26 mg/dl)
(p < 0.001). Although mean serum calcium increased after
remission, it was not statistically different from that during
remission (p > 0.05 in both groups).
Serum phosphorus was significantly lower during
disease activity in UC and CD patients (3.40 +/− 1.14
and 3.57 +/− 0.93 mg/dl respectively) compared to
remission values (5.16 +/− 0.54 and 5.10 +/− 0.48 mg/dl
respectively) and the control group (5.22 +/− 0.48 mg/dl)
(p < 0.001). Values during remission were not different
from those of controls (p > 0.05).
Serum alkaline phosphatase was significantly higher in
UC and CD patients during flare compared to values
during remission and controls with p values of <0.0001
for all. However, remission values of both groups were
not different from control group.
Similarly, urinary phosphorus was significantly higher
during flare in both UC and CD patients (2.01 +/− 0.77
and 2.06+/− 0.69 g/24 hours urinary output respectively)
compared to remission (0.66 +/− 0.26 and 0.61+/− 0.18
g/24 hours urinary output respectively) and controls
(0.74 +/− 0.19 g/24 hours urinary output) (p < 0.001).
Values during disease remission were not different from
control ones.
Serum creatinine was not different between cases (flare
or remission) and controls.
The 25 hydroxy vitamin D3 values were significantly
lower during disease flare compared to control values.
Remission values were not significantly different from
values during disease activity, or from control values
(Table 1). On the other hand, 1, 25 (OH)2 vitamin D3
values were significantly higher during flare of UC and
CD compared to controls (Table 1).
FGF23 serum levels were significantly higher during
disease flare in UC and CD patients compared to
controls. Although values significantly decreased
during remission, they remained higher than controls
(Table 1).
Table 1 Comparisons of biochemical laboratory bone markers among patients and controls
Control (I) UC Flare (IIa) UC Remission (IIb) IIa vs IIb t (p) CD Flare (IIIa) CD Remission (IIIb) IIIa vs IIIb t (p)
BMD (g/cm2) 0.74 +/−0.14 0.91 +/−0.11 −5.15 0.73 +/−0.13 0.92 +/−0.12 −4.34
(<0.0001) (<0.0001)
Z score for BMD −3.47 +/−1.75 −1.02 +/−1.21 −5.97 −3.24 +/−2.20 0.06 +/−1.48 −5.57
(<0.0001) (<0.0001)
25 (OH) VD3 (ng/ml) 47.14+/−11.78 37.41 +/−16.69 40.96 +/−12.53 −0.89 34.40 +/−19.21 42.00 +/−15.49 −1.38
(0.38) (0.176)
Comparison with control T 2.27 −1.74 2.58 1.2
(p) (0.028) (0.089) (0.014) (0.237)
1, 25 (OH)2 VD3 (pg/ml) 30.86 +/−6.67 56.11 +/−12.11 30.96 +/−8.14 8.96 65.65+/−14.99 22.80+/−3.70 12.403
(<0.0001) (<0.0001)
Comparison with control T 8.59 0.05 9.68 −4.75
(p) (<0.0001) (0.96) (<0.0001) (<0.0001)
FGF23 (pg/ml) 16.90+/−4.91 62.22 +/−20.70 26.89 +/−8.83 8.157 67.75 +/−18.36 23.55 +/−9.95 9.465
(<0.0001) (<0.0001)
Comparison with control T 9.80 4.64 12.25 2.73
(p) (<0.0001) (<0.0001) (<0.0001) (0.009)
PTH 38.410 +/−19.98 67.71 +/−20.930 55.32 +/−17.23 0.81 62.62 +/−23.07 51.81+/−20.58 0.65
0.42 0.52
−5.01 −3.21 −3.68 −2.17



















Table 2 Frequency of osteopenia and osteoporosis in flare and remission of UC and CD patients
Normal BMD (BMD>−1) Abnormal BMD Mild degree (BMD −1 to −2.5) Severe degree (< −2.5) Chi squre (P)
UC Flare 3 (11.1%) 24 (88.9%) 0 24 (88.9%) 6.17
remission 11 (40.7) 16 (59.3%) 6 (22.2%) 10 (37%) (p = 0.013)
CD Flare 3 (15%) 17 (85%) 2 (10%) 15 (75%) 14.55 (p< 0.0001)
remission 15 (75%) 5 (25%) 3 (15%) 2 (10%)
All IBD Flare 6 (12.77%) 41 (87.2%) 2 (4.23%) 39 (82.98%) 18.95 (p< 0.0001)
remission 26 (55.32%) 21 (44.7%) 9 (19.15%) 12 (25.53%)
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UC flare and remission as well as CD flare and remission
than controls. Flare of UC showed significant higher
values than their remission values (p = 0.019). Flare and
remission values in CD were not different. Comparison
of UC versus CD showed no significant differences.
Regression analysis in the ulcerative colitis group
during flare showed the only significant determining
factors were FGF23 followed by serum calcium.
Regression analysis of BMD in CD group during flare
(adjusted R2 = 0.971) showed many significant determining
factors affecting BMD. On top comes 1, 21 (OH)2 VD,
followed by urinary phosphorus and FGF23 (P <0.0001 for
all).
Although the number of CD patients treated with
infliximab is very small; the analysis of their BMD and
FGF23 showed interesting results. Z score for BMD
showed dramatic improvement to normal values in
the 6 patients (0.89 +/− 0.67) compared to their flare
(−3.32 +/− 2.31) with p value <0.0001. They showed
simultaneous decrease of FGF23 to completely nor-
mal values in remission (15.38 +/− (3.11)) compared
to flare (69.23 +/− (19.34)) with a p value <0.0001.Discussion
BMD
The diminished BMD during flare with significant
improvement in remission agrees with previous similar
results in IBD patients using either total body or lumbar
spine bone mineral density [38-40]. Herzog et al. [41]
and Ahmed et al. [42] reported significant values of 26%
and 22% respectively. Schmidt et al. [40] showed no
difference between UC and CD regarding the frequency
of low BMD.Table 3 Comparison of rate of changes of Z score of
BMD between remission and flare among patients with
UC and CD










−85.43 +/− 60.94 −111.53 +/− 62.13 1.826 0.074This degree of improvement was achieved in a period
of 7.12 +/− 2.8 months between the flare and remission
assessment. Improvement of BMD in such a relatively
short period is consistent with Viapiana et al. [43] who
found that a 3 months period of intensive nutritional
therapy in anorexia nervosa was sufficient to show the
significant improvement in BMD. Similarly, Bhambri
et al. [44] found that BMD measured by DXA was
significantly improved but not to base line after therapy
for 2.8+/−1.4 months.
The residual diminished BMD in a significant propor-
tion of IBD children, during remission, suggests that
nutritional therapy, IBD specific therapy and/or their
duration are not sufficient to restore BMD to complete
normality.
Vitamin D
The mean serum level of 25 (OH) vitamin D3, as a meas-
ure of vitamin D status [45], showed significantly lower
values during flare of UC and CD compared to controls.
Deficiency (< 15 ng/ml) or severe deficiency (< 8 ng/ml)
were uncommon among patients with IBD during flare
and markedly improved after remission. The vitamin D
nutritional state returned to normal after achieving
disease remission, although the intake of vitamin D and
calcium had not changed. This may indicate that the
state of hypovitaminosis D is a reflection of disordered
bioavailability with disease activity rather than isolated
nutritional deficiency. The normalization of vitamin D
nutritional status with residual low bone mineral density
in IBD patients implies that VD is not the sole player in
the development of IBD osteopathy. Sentongo et al. [28]
found that there was no association between hypovitami-
nosis D and bone mineral density (P = 0.10) and Hessov
et al. [6] found reduction in trabecular bone mass in
the presence of normal mean serum levels of the
three vitamin D metabolites (25-hydroxyvitamin D3,
24,25-dihydroxyvitamin D3, and 1,25-dihydroxyvitamin
D3) after ileal resection in CD. Higher values of 1,25-
dihydroxyvitamin D3 during flare of UC and CD may be
due to inflammation-induced intestinal over-expression
of activating enzymes. Abreu et al. [8] also demonstrated
high levels of 1,25- dihydroxyvitamin D3 in IBD patients,
more so in CD patients. They explained this by
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hydroxylase in CD patients which would contribute to
increased activation of vitamin D. This may be reinforced
by our finding that levels of active form were dramatically
reduced to control values or even less after achieving dis-
ease remission.
FGF23
FGF23 was significantly higher during disease flare in both
UC and CD groups, and while significantly decreasing
during remission, did not return back to normal control
values. Although phosphatonins including FGF23 inhibit 1
α hydroxylase enzyme in the kidney [10] yet, the high levels
of active vitamin D in this study minimizes this role in our
context
This finding was not reported in previous clinical stud-
ies on IBD patients. It would be related to the high
values of TNF alpha reported in such patients [17]. Uno
et al. [18] demonstrated that in experimental animals,
TNF-alpha decreases Phex mRNA and protein expression
via a transcriptional mechanism and this is at least in part
responsible for inhibition of osteoblast mineralization. The
Phex mRNA and protein is known to be involved in
degradation of FGF23 [46]. So we can propose that higher
values of FGF23 with its phosphaturic action [10] and the
resultant hypophosphatemia may share, among other fac-
tors, in the process of diminished BMD in these particular
patients. The high levels of FGF23 cannot be attributed to
impaired renal functions as serum creatinine was within
normal for all patients. 1,25-dihydroxyvitamin D3 may exert
its largest effect on FGF23 expression/production when
exposed to high levels of extracellular Pi in osteoblasts/
osteocytes [47].
PTH
Parathyroid hormone was found to be significantly
higher during disease flare than in remission. Moreover,
remission values are still significantly higher than in
controls. The relation of PTH to bone metabolism is estab-
lished. This establishes the role of altered PTH in the
cascade of osteopathy seen in these cases. The FGF23
polypeptide also suppresses the expression of vitamin D
1-hydroxylase and PTH, resulting in a reduction in serum
1,25-dihydroxyvitamin D3 [48] and PTH [49] levels. So our
results, showing high 1, 25(OH)2 VD3 and PTH, suggest
that FGF23 elevation is a secondary event rather than a
primary incident. The TNF alpha role may augment this
elevation through decrease of FGF23 degradation.
The predictors of decreased BMD
The etiology of IBD related bone disease seems to be
multi-factorial with inflammation itself being the most
important factor [4]. In our present work, bone mineral
density was low during disease flare despite absence ofsteroid therapy for at least 3 months prior to enrolment.
It dramatically increased after remission even with the
use of steroids in all patients. This may suggest a lesser
role of steroids on the bone mineral density in IBD
patients. Walther et al. [50] found a similar proportion
of osteoporosis in steroid-naive (12%) and steroid-treated
(11%) pediatric IBD patients. Paganelli et al. [4] reported
that the correlation between the lifetime cumulative dose
of steroids or duration of treatment and BMD was not
statistically significant.
Regression analysis for different clinical and laboratory
variables in the ulcerative colitis showed that the only
significant determining factors were FGF23 followed by
serum calcium. On the other hand in CD, it showed
many significant determining factors affecting BMD. On
top comes 1,25-dihydroxyvitamin D3, followed by urinary
phosphorus and FGF23. The significant role of vitamin
D in CD rather than in UC group may reflect a
problem related to inflammation or absorption in the
former group.
Previous studies have found that BMI correlated with
BMD in IBD both in children [39]. But our analysis did
not show an impact of BMI on the BMD in view of
other variables.
The marked improvement noted in our CD group might
be related to use of infliximab, a TNF inhibitor, in some of
them. Franchimont et al. [51] and Ryan et al. [52] found
that Infliximab rapidly improves bone formation in adults
with IBD.
Controversy exists about the relation between
decreased BMD and fracture risk among children with
IBD [53]. However, low BMD during childhood is
associated with increased fracture risk later in life [54].
Bone metabolism in children is characterized by
predominant bone modeling with simultaneous activity
of both osteoblasts and osteoclasts on different parts of
the bone. Therefore, the principles of bone loss observed
in adult patients with chronic inflammation are not
directly applicable to children [55]. Understanding the
specific underlying mechanisms for decreased BMD
among children with IBD may help to implement more
effective therapies for this complication.
Conclusion
We can conclude that BMD is significantly low in IBD
during disease flare with significant improvement after
remission. This osteopathy is multifactorial with a proposed
new place for the elevated FGF23 levels in such a complex
interplay.
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